Skip to main content

Advertisement

SpringerLink
Log in

Office-based Management of Recurrent Respiratory Papilloma

  • Recurrent Respiratory Papilloma (L Akst, Section Editor)
  • Published:
Current Otorhinolaryngology Reports Aims and scope Submit manuscript

Abstract

This review will highlight the indications and benefits of office-based therapy for recurrent respiratory papillomatosis (RRP) and discuss the utilization of photodynamic lasers and adjuvant medical therapy in office-based settings. Office-based management of RRP allows for more timely interventions, is preferred by the majority of patients, and negates the risk of general anesthesia. Current literature argues for the utilization of KTP laser over CO2 laser for office-based treatment of RRP. Medical therapies for RRP are limited, but agents such as bevacizumab are promising and have been shown to reduce disease burden. Medical therapies that can induce disease remission are still needed. Office-based procedures save time and healthcare expenses compared to like procedures in the operating room. However, the increased frequency for office-based procedures predicts similar overall healthcare costs for office-based and OR laser excision of RRP. Office-based management of RRP is a feasible and well-tolerated strategy in appropriately selected patients with adequate local anesthesia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Elsberg L. Laryngoscopal surgery illustrated in the treatment of morbid growths within the larynx. Philadelphia: Collins; 1866.

    Google Scholar 

  2. Bennett RS, Powell KR. Human papillomaviruses: associations between laryngeal papillomas and genital warts. Pediatr Infect Dis J. 1987;6(3):229–32.

    Article  CAS  PubMed  Google Scholar 

  3. Mounts P, Shah KV, Kashima H. Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proc Natl Acad Sci USA. 1982;79(17):5425–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Morgan AH, Zitsch RP. Recurrent respiratory papillomatosis in children: a retrospective study of management and complications. Ear Nose Throat J. 1986;65(9):19–28.

    CAS  PubMed  Google Scholar 

  5. Shykhon M, Kuo M, Pearman K. Recurrent respiratory papillomatosis. Clin Otolaryngol Allied Sci. 2002;27(4):237–43.

    Article  CAS  PubMed  Google Scholar 

  6. Derkay CS. Task force on recurrent respiratory papillomas: a preliminary report. Arch Otolaryngol Head Neck Surg. 1995;121(12):1386–91.

    Article  CAS  PubMed  Google Scholar 

  7. Shah KV, Stern WF, Shah FK, Bishai D, Kashima HK. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J. 1998;17(5):372–6.

    Article  CAS  PubMed  Google Scholar 

  8. Silverberg M. Condyloma in pregnancy is strongly predictive of Juvenile-Onset recurrent respiratory papillomatosis. Obstet Gynecol. 2003;101(4):645–52.

    PubMed  Google Scholar 

  9. Kashima HK, Shah F, Lyles A, Glackin R, Muhammad N, Turner L, et al. A comparison of risk factors in Juvenile-Onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope. 1992;102(1):9–13.

    Article  CAS  PubMed  Google Scholar 

  10. Kocjan BJ, Gale N, Hocevar Boltezar I, Seme K, Fujs Komlos K, Hosnjak L, et al. Identical human papillomavirus (HPV) genomic variants persist in recurrent respiratory papillomatosis for up to 22 years. J Infect Dis. 2013;207(4):583–7.

    Article  CAS  PubMed  Google Scholar 

  11. Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP task force. Arch Otolaryngol Head Neck Surg. 1999;125(7):743–8.

    Article  CAS  PubMed  Google Scholar 

  12. Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2000;126(8):935–9.

    Article  CAS  PubMed  Google Scholar 

  13. Chadha NK, Allegro J, Barton M, Hawkes M, Harlock H, Campisi P. The quality of life and health utility burden of recurrent respiratory papillomatosis in children. Otolaryngol-Head Neck Surg. 2010;143(5):685–90.

    Article  PubMed  Google Scholar 

  14. • Zeitels SM, Franco RA, Dailey SH, Burns JA, Hillman RE, Anderson RR. Office-based treatment of glottal dysplasia and papillomatosis with the 585-nm pulsed dye laser and local anesthesia. Ann Otol Rhinol Laryngol. 2004;113(4):265–76. This is the first study reporting the feasibility and efficacy of office-based therapy in the management of RRP. In this study 77 of 82 procedures were tolerated and able to be completed, and that 50 % disease involution was achieved in 88 % (68/77) of those cases.

  15. Rees C, Halum S, Wijewickrama R, Koufman J, Postma G. Patient tolerance of in-office pulsed dye laser treatments to the upper aerodigestive tract. Otolaryngol Head Neck Surg. 2006;134(6):1023–7. 

  16. Rees CJ, Postma GN, Koufman JA. Cost savings of unsedated office-based laser surgery for laryngeal papillomas. Ann Otol Rhinol Laryngol. 2007;116(1):45–8. 

  17. Kuo CY, Halum SL. Office-based laser surgery of the larynx: cost-effective treatment at the office’s expense. Otolaryngol-Head Neck Surg. 2012;146(5):769–73.

  18. • Hillel AT, Ochsner MC, Johns MM 3rd, Klein AM. A cost and time analysis of laryngology procedures in the endoscopy suite versus the operating room. Laryngoscope. 2015. doi:10.1002/lary.25653. This study demonstrates an innovative solution for addressing the financial disincentive of office-based laryngeal procedures. The use of the endoscopy suite or the redesigation of “unregulated” clinical space to “regulated” space can remove the financial burden of unsedated laryngeal procedures while maintaining the overall cost savings touted for office-based procedures.

  19. Wang SX, Simpson CB. Anesthesia for office procedures. Otolaryngol Clin North Am. 2013;46(1):13–9.

  20. Gadkaree SK, Best SR, Walker C, Akst LM, Hillel AT. Patient tolerance of transoral versus percutaneous thyrohyoid office-based injection laryngoplasty: a case-controlled study of forty-one patients. Clin Otolaryngol. 2015;40(6):717–21.

  21. Sulica L, Blitzer A. Anesthesia for laryngeal surgery in the office. Laryngoscope. 2000;110(10 Pt 1):1777–9.

  22. Dedo HH, Yu KCY. CO2 laser treatment in 244 patients with respiratory papillomas. Laryngoscope. 2001;111(9):1639–44.

  23. Ossoff RH, Werkhaven JA, Dere H. Soft-tissue complications of laser surgery for recurrent respiratory papillomatosis. Laryngoscope. 1991;101(11):1162–6.

  24. Hartnick CJ, Boseley ME, Franco RA, Cunningham MJ, Pransky S. Efficacy of treating children with anterior commissure and true vocal fold respiratory papilloma with the 585-nm pulsed-dye laser. Arch Otolaryngol Head Neck Surg. 2007;133(2):127–30. 

  25. McMillan K, Pankratov MM, Wang Z, Bottrill I, Rebeiz EE, Shapshay SM. Atraumatic laser treatment for laryngeal papillomatosis. In: Anderson RR, editor. 1994 [cited 2015 Dec 10]. p. 104–10. Available from: http://proceedings.spiedigitallibrary.org/proceeding.aspx?articleid=950870.

  26. Mcmillan K, Shapshay SM, McGilligan JA, Wang Z, Rebeiz EE. A 585-nanometer pulsed dye laser treatment of laryngeal papillomas: preliminary report. Laryngoscope. 1998;108(7):968–72.

  27. Franco RA, Zeitels SM, Farinelli WA, Anderson RR. 585-nm pulsed dye laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol. 2002;111(6):486–92.

  28. Tan OT, Hurwitz RM, Stafford TJ. Pulsed dye laser treatment of recalcitrant verrucae: a preliminary report. Lasers Surg Med. 1993;13(1):127–37.

  29. Anderson RR, Parrish JA. Microvasculature can be selectively damaged using dye lasers: a basic theory and experimental evidence in human skin. Lasers Surg Med. 1981;1(3):263–76.

  30. Zeitels SM, Akst LM, Bums JA, Hillman RE, Broadhurst MS, Anderson RR. Pulsed angiolytic laser treatment of ectasias and varices in singers. Ann Otol Rhinol Laryngol. 2006;115(8):571–80.

  31. •• Zeitels SM, Akst LM, Burns JA, Hillman RE, Broadhurst MS, Anderson RR. Office-based 532-nm pulsed KTP laser treatment of glottal papillomatosis and dysplasia. Ann Otol Rhinol Laryngol. 2006;115(9):679–85. This study demonstrates the safety and efficacy of office-based utilization of the KTP laser for RRP. The KTP laser has a better photodynamic profile compared to that of the PDL laser.

  32. Broadhurst MS, Akst LM, Burns JA, Kobler JB, Heaton JT, Anderson RR, et al. Effects of 532 nm pulsed-KTP laser parameters on vessel ablation in the avian chorioallantoic membrane: implications for vocal fold mucosa. Laryngoscope. 2007;117(2):220–5.

  33. Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9–10):397–408. 

  34. De Schutter T, Andrei G, Topalis D, Naesens L, Snoeck R. Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. BMC Med Genomics. 2013;6:18.

  35. Pransky SM, Magit AE, Kearns DB, Kang DR, Duncan NO. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg. 1999;125(10):1143–8. 

  36. Fusconi M, Grasso M, Greco A, Gallo A, Campo F, Remacle M, et al. Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir. Acta Otorhinolaryngol Ital. 2014;34(6):375–81. 

  37. Grasso M, Remacle M, Bachy V, Van Der Vorst S, Lawson G. Use of cidofovir in HPV patients with recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2014;271(11):2983–90.

  38. McMurray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol. 2008;117(7):477–83.

  39. Wemer RD, Lee JH, Hoffman HT, Robinson RA, Smith RJH. Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2005;114(11):836–9.

  40. Broekema FI, Dikkers FG. Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2008;265(8):871–9.

  41. Zeitels SM, Lopez-Guerra G, Burns JA, Lutch M, Friedman AM, Hillman RE. Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol Suppl. 2009;201:1–13.

  42. Rahbar R, Vargas SO, Folkman J, McGill TJ, Healy GB, Tan X, et al. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2005;114(4):289–95.

  43. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 2007;41(4):614–25.

  44. Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs. 2014;74(16):1891–925. 

  45. •• Zeitels SM, Barbu AM, Landau-Zemer T, Lopez-Guerra G, Burns JA, Friedman AD, et al. Local injection of bevacizumab (avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol. 2011;120(10):627–34. This study, prospective in nature, demonstrates that the addition of intralesional bevacizumab to KTP laser therapy enhances disease involution compared to KTP laser therapy alone, and that in 16 of 17 cases the combination of KTP laser and adjuvant bevacizumab had improved disease regression compared to KTP laser alone.

  46. Best SR, Friedman AD, Landau-Zemer T, Barbu AM, Burns JA, Freeman MW, et al. Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2012;121(9):587–93.

  47. Sidell DR, Nassar M, Cotton RT, Zeitels SM, de Alarcon A. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2014;123(3):214–21.

  48. Peng S, Best SR, Hung C-F, Loyo M, Lyford-Pike S, Flint PW, et al. Characterization of human papillomavirus type 11-specific immune responses in a preclinical model. Laryngoscope. 2010;120(3):504–10.

  49. Villa LL, Ault KA, Giuliano AR, Costa RLR, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine. 2006;24(27–28):5571–83.

  50. Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. J Voice. 2015;29(2):223–9. 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology – Head and Neck Surgery, Johns Hopkins School of Medicine, 601 N. Caroline Street, JHOC 6th Floor, Baltimore, MD, 21287, USA

    Kevin M. Motz & Alexander T. Hillel

Authors
  1. Kevin M. Motz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander T. Hillel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander T. Hillel.

Additional information

This article is part of the Topical Collection on Recurrent Respiratory Papilloma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Motz, K.M., Hillel, A.T. Office-based Management of Recurrent Respiratory Papilloma. Curr Otorhinolaryngol Rep 4, 90–98 (2016). https://doi.org/10.1007/s40136-016-0118-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40136-016-0118-0

Keywords

Search

Navigation